FPS
KYNB

Fieldpoint Private Securities’s Kyntra Bio KYNB Stock Holding History

Fieldpoint Private Securities’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-55
Closed -$47K – 1575
2021
Q1 		$47K Sell
55
-16
-23% -$17K 0.01% 584
2020
Q4 		$65K Buy
+71
New +$74.6K 0.01% 445
2020
Q1 		– Sell
-210
Closed -$226K – 356
2019
Q4 		$226K Buy
210
+129
+159% +$132K 0.07% 250
2019
Q3 		$75K Sell
81
-7
-8% -$7.69K 0.03% 339
2019
Q2 		$100K Buy
+88
New +$96.3K 0.03% 328

Other funds holding KYNB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fieldpoint Private Securities's KYNB Position: Q2 2021 in Review

Fieldpoint Private Securities sold out of Kyntra Bio (KYNB) in Q2 2021, closing a stake of 55 shares — an estimated $47K sold.

Fieldpoint Private Securities first reported a position in KYNB in Q2 2019 and held it in 5 quarters. The position peaked at $226K in Q4 2019. 174 funds tracked by Wall St. Rank hold KYNB as of Q2 2021.

  • Fieldpoint Private Securities reported no remaining Kyntra Bio position as of Q2 2021 after selling out during the quarter.
  • Fieldpoint Private Securities sold 55 Kyntra Bio shares in Q2 2021, an estimated $47K.
  • Fieldpoint Private Securities first reported a position in Kyntra Bio in Q2 2019 and held it in 5 quarters.
  • Fieldpoint Private Securities's Kyntra Bio position peaked at $226K in Q4 2019.
  • 174 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2021.

Based on Fieldpoint Private Securities's 13F filing for Q2 2021, filed 12 Aug 2021.